Table 5.

Compounds with senotherapeutic potential.

Compounds	Mechanisms	References
Senolytics
Polyphenols
Fisetin	Activates caspases-7,8 and 9.	[1109]
Quercetin	Inhibits PI3K, other kinases, and serpines.	[114]
EF24 (curcumin analog)	Downregulates the Bcl-2 family proteins.	[1110]
Apigenin	NF-κB p65 inhibitor.	[1111]
Kaempferol	NF-κB p65 inhibitor.	[1111]
Alkaloids
Piperlongumine	Activates caspase-3. Degradation of PARP.	[1112]
Cardiac glycosides
Ouabain	Inhibitor of Na+/K+ ATPase on the plasma membrane.	[1113]
Digoxin	Inhibitor of Na+/K+ ATPase on the plasma membrane.	[1114]
Synthetic compounds
Dasatinib	Inhibitor of multiple tyrosine kinases (alone and in the combination with Quercetin).	[114]
Azithromycin	Induces both aerobic glycolysis and autophagy.	[1115]
Fenofibrate	PPARα agonist.	[1116]
Panobinostat	Non-selective HDAC inhibitor.	[1117]
ABT-737	BCL-2, BCL-W, and BCL-XL inhibitor.	[1118]
A-1331852	Selective BCL-XL inhibitor.	[1109]
A-1155463	Selective BCL-XL inhibitor.	[1109]
FOXO4-DRI (modified FOXO4-p53 interfering peptide)	It causes p53 nuclear exclusion and cell-intrinsic apoptosis.	[1119]
Navitoclax (ABT-263)	Bcl-2 family inhibitor.	[1120]
17-DMAG	HSP90 inhibitor.	[1121]
17AAG	HSP90 inhibitor.	[1121]
AT13387	HSP90 inhibitor.	[1121]
BIIB021	HSP90 inhibitor.	[1121]
Geldanamycin	HSP90 inhibitor.	[1121]
Ganetespib	HSP90 inhibitor.	[1121]
NYP-AUY922	HSP90 inhibitor.	[1121]
PU-H71	HSP90 inhibitor.	[1121]
Senomorphics
Synthetic compounds
Rapamycin	mTOR inhibitor.	[1122]
Ruxolitinib	JAK inhibitor.	[1123]
Trichostatin A and Vorinostat	HDAC inhibitors.	[1124]
Mirin	Inhibitor of MRE11-mediated end resection.	[1124]
SP600125	JNK inhibitor.	[1124]
Nutlin-3a	MDM2 inhibitors.	[1125]
MI-63	MDM2 inhibitors.	[1125]
SB203580	p38 inhibitor.	[1126]
UR-13756	p38 inhibitor.	[1127]
BIRB 796	p38 inhibitor.	[1127]
PF-3644022	MK2 inhibitor.	[1127]
MK2.III	MK2 inhibitor.	[1127]
JQ1	BRD4 inhibitor.	[1128]
I-BET762	BRD4 inhibitor.	[1128]